The week in review

Big news in the diabetes and weight loss world this week, with a crackdown on the compounding of Ozempic and Mounjaro Compounding pharmacies are set to be prohibited from producing replicas of Ozempic (semaglutide) and Mounjaro (tirazapetide) following reports of severe adverse events after taking compounded versions of the drugs. Reactions were mixed, with the